Please sign in to follow a disease.
Could a daily supplement boost depression therapy?
NCT ID NCT07416747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a dietary supplement called GynMDD, taken alongside weekly supportive therapy, can improve symptoms of mild to moderate depression more than therapy plus a placebo. 168 adults aged 18 to 65 will take either the supplement or a placebo daily for 8 weeks, complete mood and digestive questionnaires, and provide stool samples. The goal is to see if the supplement reduces depression scores and improves gut health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GynMDD (a dietary supplement containing L-glutamine, curcumin, and probiotic bacteria)
- What this could lead to
- If it works, this could offer a simple, natural add-on to therapy for people with mild to moderate depression, potentially improving mood and digestive health.
- What could go wrong
- This is an early-stage, small trial (168 people) testing a dietary supplement, not a drug. The supplement may show no extra benefit over placebo, and results may not apply to severe depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 168 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 to 65 years, inclusive * The main reason for consultation is a suspected depressive episode * MADRS score between 15 and 34, indicating mild to moderate depression * No suicidal risk, defined as a score of 0 on item 10 of the MADRS scale * Body Mass Index (BMI) between 19 and 29 (inclusive) * Signed informed consent, confirming that the participant understands the purpose and requirements of the study and agrees to comply with the procedures (including scheduled supportive psychotherapy sessions) * Affiliation with the French national health insurance system or beneficiary of such coverage Exclusion Criteria: * History of severe psychiatric disorders or currently undergoing supportive psychotherapy * Confirmed suicidal risk, defined as a score between 1 and 6 on MADRS item 10 * Current treatment with antidepressants (AD) * MADRS score \> 34 * Conditions in which probiotic administration is not recommended (e.g., immunodeficiency, presence of a venous catheter) * Allergy to any component of the placebo or the GynMDD dietary supplement * Current consumption of probiotic-based dietary supplements * Recent infectious episodes that may require antibiotic therapy * Current treatment with anxiolytics * Long-term chronic anti-inflammatory treatment * Alcohol abuse, defined as a consumption of 10 standard drinks per week or more * Use of illicit drugs or substances of abuse * Inability to provide informed consent * Participation in another clinical study within the past 12 months * Pregnant or breastfeeding women * Patients without health insurance * Individuals under legal protection, guardianship, trusteeship, or any other protective measure
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depression are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Albert Chenevier 40 rue de Mesly
Créteil, 94010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a Text-Message program help trauma survivors avoid PTSD and depression?
- Can a website help young people understand depression?
- Can a brain scan and your phone predict where depression goes next?
- Can a tailored therapy ease anxiety and depression in autistic teens?
- Reading the Brain's signals to predict who benefits from deep brain stimulation